Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

Status Completed

Clinical Trial Summary

This is a single-center study to investigate the effects of a topical cream on patients 12 years of age and older that have been diagnosed with epidermolysis bullosa.

Clinical Trial Description

The trial will be conducted in patients with any form of Epidermolysis Bullosa (EB) with at least 1 active EB wound between 2.5 and 50 cm2 in size or up to 10% of the Body Surface Area. The investigators will identify an "index lesion" and other lesions for treatment An area of un-involved skin will also be treated with the study cream. This are will be used for testing by producing tiny blisters th so that the underlying tissue can be examined using a special microscope.

Patients will apply the study cream ;

Study Design

Related Conditions & MeSH terms

Epidermolysis Bullosa

Clinical Trial Details

NCT number	NCT02793960
Study type	Interventional
Source	University of Miami
Contact
Status	Completed
Phase	Phase 1
Start date	August 10, 2016
Completion date	August 26, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00380640` - The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa	Phase 2
Completed	`NCT00004761` - Establishment of the National Epidermolysis Bullosa Registry	N/A
Completed	`NCT01263379` - Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa	Phase 1/Phase 2
Completed	`NCT01716169` - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care	N/A
Withdrawn	`NCT01454687` - Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes	N/A
Completed	`NCT00014729` - Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa	Phase 1
Recruiting	`NCT05838092` - Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)	Phase 3
Recruiting	`NCT03269474` - Computational Drug Repurposing for All EBS Cases
Completed	`NCT03068780` - Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa	Phase 3
Terminated	`NCT02090283` - Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa	Phase 2
Completed	`NCT02582775` - MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs	Phase 2
Recruiting	`NCT04213703` - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Completed	`NCT02384460` - ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa	Phase 3
Terminated	`NCT02670330` - Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa	Phase 3
Terminated	`NCT01619670` - A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa	Phase 4
Recruiting	`NCT01340235` - Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin	Phase 3
Completed	`NCT02014376` - Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa	Phase 2
Completed	`NCT04217538` - Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
Completed	`NCT03942250` - Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients	N/A
Completed	`NCT01033552` - Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs	Phase 1/Phase 2